Profil
Christine Murray is Senior VP-Global Regulatory Affairs at Cytokinetics, Inc. since 2023.
Former roles include Independent Director at Eiger BioPharmaceuticals, Inc. from 2019 to 2024; Vice President-Regulatory Affairs at Achaogen, Inc. from 2011 to 2015; Vice President-Global Regulatory Affairs at Horizon Pharmaceutical LLC from 2015 to 2017; Vice President-Regulatory Affairs at Raptor Pharmaceuticals, Inc. from 2015 to 2017; and Senior Vice President-Global Regulatory Affairs at Ultragenyx Pharmaceutical, Inc. from 2018 to 2021.
Education includes undergraduate studies at The University of Liverpool and graduate studies at Newcastle University.
Postes actifs de Christine Murray
| Sociétés | Poste | Début |
|---|---|---|
| CYTOKINETICS, INCORPORATED | Conseiller Juridique Général | 01/04/2023 |
Anciens postes connus de Christine Murray
| Sociétés | Poste | Fin |
|---|---|---|
| EIGER BIOPHARMACEUTICALS | Directeur/Membre du Conseil | 15/03/2024 |
| ULTRAGENYX PHARMACEUTICAL INC. | Conseiller Juridique Général | 01/09/2021 |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and markets life-altering therapeutics | Corporate Officer/Principal | 01/02/2017 |
| RAPTOR PHARMACEUTICAL CORP | Conseiller Juridique Général | 01/01/2017 |
| ACHAOGEN | Conseiller Juridique Général | 02/01/2015 |
Formation de Christine Murray
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Cytokinetics, Inc.
Cytokinetics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes novel drug products | Health Technology |
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections | Health Technology |
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
The University of Liverpool
The University of Liverpool Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Newcastle University
Newcastle University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Horizon Pharmaceutical LLC
Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of life-altering therapeutics that treat debilitating and often fatal diseases | Health Technology |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and markets life-altering therapeutics | Health Technology |
Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies to treat and cure hepatitis delta virus and other serious diseases | Health Technology |
















